Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful i...

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer  AstraZeneca

A new commitment for vaccine equity and defeating the pandemic - World Bank Blogs

A new commitment for vaccine equity and defeating the pandemic  World Bank Blogs

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful impro...

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer  AstraZeneca

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in d...

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial  AstraZeneca

Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refracto...

Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early  AstraZeneca